Boston Scientific falls on FDA warning, Guidant results
Will the Boston Scientific/Guidant/Abbott deal close? The market seems to think there’s a good chance it won’t. If it doesn’t, look for J&J to make a reduced-value offer for Guidant (under $70/share). If it does, look for J&J and Abbott to benefit most (after Guidant stockholders, of course) from the over-priced deal. Boston Scientific shareholders comes out on the losing end of this deal either way in my estimation.
